Introduction {#Sec1}
============

Soft tissue sarcomas (STS) are a rare group of mesenchymal tumors comprising approximately 1 % of all malignancies \[[@CR1]\]. Surgical resection and pre- or postoperative irradiation is the standard treatment for locally advanced STS of the extremities \[[@CR2], [@CR3]\]. In retroperitoneal STS preoperative radiation therapy (RT) is currently under investigation in a phase III trial after cohort studies had demonstrated that preoperative RT may decrease local recurrence and improve overall survival \[[@CR4], [@CR5]\]. (EORTC STRASS trial ClinicalTrials.gov Identifier: NCT01344018) Despite improvements in irradiation techniques such as intensity modulated radiation therapy (IMRT) local recurrence rates of large, high grade STS is still up to 20 % in extremity and 40 % in retroperitoneal tumors and there is a definitive need to improve local therapy \[[@CR6], [@CR7]\].

Receptor tyrosine kinase inhibitors such as sunitinib exhibit antiproliferative and anti-angiogenic properties \[[@CR8]\]. Experimental data demonstrated that concurrent treatment with sunitinib and RT is more effective than RT alone in engineered mouse models of soft tissue sarcoma \[[@CR9]\]. Thus, concurrent treatment seems to lead to additive effects. Jain et al. postulated even synergistic effects if anti-angiogenic treatment is administered upfront RT by "normalizing" the chaotic neovascularization of tumors \[[@CR10]\]. Vascular normalization may then lead to decreased tumor hypoxia and consequently to increased RT efficacy.

Here we report the results of a phase I trial of concurrent sunitinib and RT in patients with locally advanced soft tissue sarcoma conducted within the German Interdisciplinary Sarcoma Group (GISG). The rationale and the design of the trial have been described in detail before \[[@CR11]\].

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This was an open-label, single-arm, single center phase I trial performed within the GISG. The study intervention was administration of sunitinib concurrently to preoperative irradiation in patients with soft tissue sarcoma. The primary endpoint of the study was to determine the recommended phase II dose of sunitinib given two weeks before and throughout standard RT as preoperative treatment. Secondary endpoints were toxicity, radiographic and pathologic treatment response as well as morbidity of tumor resection. A standard dose escalation 3 + 3 design with two dose levels was used.

The sponsor of the trial was the University of Heidelberg, Germany. The study was funded by the German Research Foundation (DFG, grant number JA 2030/1) and the Medical Faculty Mannheim, University of Heidelberg, Germany. The study medication was provided by Pfizer Oncology Germany. Pfizer had no influence on design, conduction or publication of the trial. The study was approved by the Ethics Committee II of the University of Heidelberg and the Federal Agency for Drugs and Medical Devices, Germany (BfArM). The trial was registered at clinicaltrials.gov (NCT01498835). The trial was performed on an outpatient basis. All patients were treated at the Mannheim University Medical Center (UMM), University of Heidelberg, Germany.

Patient selection {#Sec4}
-----------------

Patients with locally advanced primary soft tissue sarcoma that required preoperative irradiation and tumor resection were included into the trial. The protocol allowed recruitment of patients with primary tumors but also with local recurrences or metachronous solitary metastatic lesions if the treatment decision was to perform RT and subsequent surgery. All tumors had to be resectable and biopsy-proven STS. Patients needed to have an age of 18 years or older with ECOG status 0 or 1 and normal organ function (left ventricular ejection fraction, kidney, liver, and bone marrow). Main exclusion criteria were metastatic disease (with the above mentioned exception), prior therapy with receptor tyrosine kinase inhibitors or conventional chemotherapy or history of myocardial infarction, congestive heart failure, stroke, thrombosis or embolism or uncontrolled medical disease such as arterial hypertension or diabetes mellitus.

Treatment regimen {#Sec5}
-----------------

The treatment plan was to administer sunitinib two weeks prior to and during intensity modulated radiation therapy (IMRT, 28 × 1.8 Gy) and to resect the tumors 5 to 8 weeks after the end of the neoadjuvant treatment. Adjuvant chemotherapy was not administered. All procedures were described in detail before \[[@CR11]\].

Sunitinib malate was orally administered as hard gelatin capsules of 25 or 12.5 mg. Sunitinib dose was escalated according to a traditional 3 + 3 design. Dose level 1 was 25 mg and dose level 2 was 37.5 mg. No further dose escalation was planned. Intrapatient dose escalation was not permitted. Sunitinib was taken starting 2 weeks prior to radiation therapy, continued throughout radiation therapy and stopped on the final day of radiation therapy. Sunitinib was administered continuously and not with a 4 weeks on/2 weeks off regimen.

Intensity-modulated radiation therapy (IMRT) was applied according to standard protocols at the Mannheim University Medical Center. The dose of IMRT was 50.4 Gy (median planning target volume (PTV) dose) administered in 28 fractions within 5.5 weeks. Dose prescription was performed at the median dose in the PTV with the 90 % isodose line covering the PTV. A CT simulation was performed to define the gross tumour volume (GTV). In case of retroperitoneal sarcomas, the clinical target volume (CTV) was the GTV with a 1,5 cm margin axially. The margin placed around the GTV in the superior-inferior direction was 2,5 cm. The planning target volume was the CTV with a 5 mm margin. In case of extremity STS the CTV margins were 2,5 cm axially and 4,5 cm in the superior-inferior direction. The dose constraint for the small intestine was 45 Gy at the maximum and the mean dose for kidneys were not greater than 10 Gy. Treatment was performed using step-and-shoot IMRT. A strip of 2--3 cm skin was spared in case of extremity STS.

Surgery was scheduled 5--8 weeks after completion of neoadjuvant treatment. Surgery was planned as compartment or wide resection in extremity STS. In retroperitoneal sarcoma, the surgical approach was a multivisceral resection including adjacent organs (e.g. colectomy, nephrectomy, splenectomy, distal pancreatectomy) and resection of abdominal wall musculature or, respectively, the psoasmuscle.

Dose limiting toxicity (DLT) and dose adjustments of sunitinib {#Sec6}
--------------------------------------------------------------

Adverse events occurring during intake of sunitinib until 4 weeks after completion of combined RT and sunitinib were documented and classified according to common toxicity criteria of adverse events (CTCAE 4.0) by weekly study visits including clinical examination, interrogation for adverse events, laboratory tests and ECG. DLTs were defined as any toxicity that causes discontinuation of RT for more than 6 days, toxicity classified grade 4 or 5 and toxicity classified grade 3 with the exception of hematologic toxicities, arterial hypertension if controlled by adequate medication within 14 days and elevated serum levels of liver and pancreas enzymes if not related to clinical symptoms. Sunitinib was stopped and not reintroduced in case of DLT. In case of grade 3 hematological toxicity sunitinib was reduced (37.5 mg to 25 mg to 12.5 mg daily) until recovery to grade 1 and then reintroduced in the original dose. Furthermore the protocol allowed a temporary dose reduction in case of prolonged toxicity of any CTCAE grade on an individual basis. All dose reductions were documented in detail. Postoperative morbidity was assessed by a study visit between the 30^th^ and 40^th^ day after tumor resection and also classified according to CTCAE 4.0.

Evaluation of treatment response {#Sec7}
--------------------------------

Imaging response was defined according to response evaluation criteria in solid tumors (RECIST) by comparing pre-treatment and preoperative magnetic resonance imaging or computed tomography. Pathological response was defined as the fraction of non-viable tumor tissue in the resection specimen with cut-off points at fifty and ninety per cent.

Results {#Sec8}
=======

Patients and tumor characteristics {#Sec9}
----------------------------------

A total of 10 patients were recruited. The cohort of dose level 1 was extended from three to six patients as planned in the study protocol since one of the first three patients suffered dose limiting toxicity. Three patients were treated at dose level 2 as planned in the study protocol. One patient was recruited into the study but actually did not meet all inclusion criteria after pathology review. Therefore this patient had to be excluded from the analysis. The patient never started study treatment and was treated by surgery alone. All following analyses are based on the nine patients treated according to the study protocol. Patient characteristics are depicted in Table [1](#Tab1){ref-type="table"}.Table 1Patient and tumor characteristicsNumber of patients9 Dose level 1 (25 mg sunitinib)6 Dose level 2 (37.5 mg sunitinib)3Gender Female3 Male6Age Median (range), years52 (29--75)Tumor siteRetroperitoneum4 Lower Extremity3 Groin1 Chest wall1Tumor size Median (range), cm11 (5--20)Grading (FNLCC) Low grade1 Intermediate grade1 High grade7Histology Dedifferentiated liposarcoma4 Undifferentiated pleomorphic sarcoma2 Myxoid liposarcoma1 Myxofibrosarcoma1 Synovial sarcoma1

Toxicity of preoperative treatment {#Sec10}
----------------------------------

At dose level 1, 1/3 initially recruited patients developed a DLT (grade 4 lymphopenia) but recovered completely after discontinuation of sunitinib. This patient had a retroperitoneal dedifferentiated liposarcoma with a size of 15 cm. The dose level 1 cohort was then expanded to six patients. None of the following dose level 1 patients developed DLT. At dose level 2, 0/3 patients developed DLT.

The most frequent toxicity of any grade (8/9) and most frequent grade 3 or 4 toxicity (5/9) was hematotoxicity. Hematotoxicity resolved in all patients before surgery and no patient developed neutropenic fever. Grade 3/4 hematotoxicity occurred at both dose levels and in patients with tumors located in the retroperitoneum as well as located in the extremities. No other grade 3 toxicity occurred. Hematotoxicity was the most frequent toxicity of any grade. Six out of nine patients required dose adjustments due to toxicity. Five patients had dose adjustments because of hematotoxicity and one patient because of prolonged grade 2 mucositis. Dose adjustments were necessary at both dose levels. In 5/6 patients with dose adjustments, dose reductions were necessary after 4 or more weeks of treatment with sunitinib. Radiation therapy was completed without toxicity related dose reductions or delays in all patients. Toxicity within the radiation field did not exceed grade 2 in any patient. One patient had a break of radiation therapy for one day due to gastrointestinal toxicity. All other patients completed radiation therapy as planned. Toxicity of combined treatment is summarized in Table [2](#Tab2){ref-type="table"}.Table 2Toxicity of study treatment and postoperative complications of the individual patientsDose levelPatientTumor siteToxicity of combined sunitinib and RT (CTCAE 4.0 grade)Radiation site toxicity (CTCAE 4.0 grade)Postoperative complications (CTCAE 4.0 grade)11Lower extremityneutropenia (3) thrombocytopenia (2) facial edema (1) fatigue (1)0prolonged wound drainage (1)12Lower extremity-0wound dehiscence (3)13Retroperitoneallymphopenia (4) neutropenia (3) thrombocytopenia (3) gamma-glutamyl-transferase elevation (2) arterial hypertension (2) fatigue (1)1-14Retroperitoneallymphopenia (3) neutropenia (2) thrombocytopenia (1) genitourinary (2) diarrhea (2)0intraoperative bleeding (4) intraabd. abscess (3) myocardial ischemia (3) anastomotic leakage (3)15Retroperitoneallymphopenia (3) neutropenia (2) thrombocytopenia (1) arterial hypertension (2) dry mouth (1) diarrhea (1)1-16Groinlymphocytopenia (3) neutropenia (1) diarrhea (2) dysgeusia (1)2-27Retroperitoneallymphopenia (2) neutropenia (2) thrombocytopenia (1) nausea (2) dry mouth (2)2-28Lower extremityneutropenia (1) thrombocytopenia (1) vaginal mucositis (2) hand foot syndrome (1) nausea (1) oral mucositis (1) epistaxis (1)2prolonged wound drainage (2) lymphedema (2)29Chest walllymphopenia (3) neutropenia (1) thrombocytopenia (1) oral mucositis (1) fatigue (1)1delayed wound healing (1)

Surgery and postoperative morbidity {#Sec11}
-----------------------------------

All patients underwent tumor resection within 4 to 10 (median 7) weeks after completion of preoperative treatment. The four patients with extremity STS underwent wide resection, one required reconstruction of the superficial femoral artery and one required plastic reconstruction with a gastrocnemius flap. Three out of four patients with retroperitoneal sarcoma underwent multivisceral resection with colectomy and nephrectomy, one patient with a retroperitoneal undifferentiated sarcoma was diagnosed with several small size liver metastases at surgery and underwent tumor resection with colectomy and without nephrectomy. One patient had a chest wall sarcoma and underwent tumor resection en bloc with chest wall and upper lobe resection. Microscopic clear margins for the primary tumor site were achieved in 7/9 patients and 2/9 patients had R1 (microscopically incomplete) resections. Five out of nine patients developed postoperative complications and 2/9 patients required re-interventions (Table [2](#Tab2){ref-type="table"}). One patient with extremity STS went back to theatre because of wound dehiscence and one patient with a retroperitoneal sarcoma had intraoperative bleeding, postoperative anastomotic leakage and abscess formation. There was no obvious difference in postoperative morbidity regarding dose level (3/5 dose level 1 vs. 2/5 dose level 2, *p* = 0.60) or sunitinib dose reductions (4/5 with dose reduction, 1/5 without dose reduction, *p* = 0.40).

Treatment response and oncological outcome {#Sec12}
------------------------------------------

Restaging before surgery showed partial response in one patient, stable disease in seven patients, and progressive disease in one patient (Table [3](#Tab3){ref-type="table"}). The patient with progressive disease had a retroperitoneal undifferentiated pleomorphic sarcoma with progression of the primary tumor and two liver metastases at surgical exploration. Pathological examination revealed ≥ 95 % non-viable tissue in 3/9 resection specimens (Table [3](#Tab3){ref-type="table"}). Histology of these patients was dedifferentiated liposarcoma, synovial sarcoma and undifferentiated pleomorphic sarcoma.Table 3Treatment response and oncological outcomePatientTumor site, histology and sizeSunitinib doseRT doseResection marginRECIST% non-viable tissueFollow-up status (and time), events (months after ED)1lower extremity, myxofibrosarcoma, 11 cm2550.4R0stable disease30 %NED (29mo), LR resected (19 mo)2lower extremity, dediff. lipo, 8 cm2550.4R0stable disease95 %AWD (36 mo), Soft tissue mets (15 mo)3Retroperitoneal, dediff. lipo, 15 cm2550.4R1stable disease75 %NED (28 mo)4Retroperitoneal, dediff. lipo, 12 cm2550.4R1stable disease20 %NED (11 mo)5Retroperitoneal, undiff. pleomorphic sarcoma, 14 cm2550.4R2 (primary Tumor R0)progressive disease (locally and mets)70 %DOD (9 mo), Liver mets at surgery6Groin, Dediff. lipo, 20 cm2550.4R0stable disease30 %NED (24 mo)7Retroperitoneal, myxoidlipo, 5 cm37.550.4R0partial response50 %NED (20 mo)8lower extremity, synovial sarcoma, 8 cm37.550.4R0stabledisease100 %AWD (23 mo), Lung mets (15 mo)9chest wall, undiff. pleomorphic sarcoma, 5 cm37.550.4R0stabledisease100 %NED (13 mo)

Median follow-up was 23 months (range 9--36 months, Table [3](#Tab3){ref-type="table"}). One patient developed a local recurrence of a myxofibrosarcoma of the thigh within the radiation field after 19 months. Three patients were diagnosed with metastatic disease. One patient with metastatic disease died during follow-up.

Discussion {#Sec13}
==========

The primary endpoint of this GISG phase I trial was to determine the recommended dose of sunitinib given concurrently with preoperative RT in locally advanced soft tissue sarcoma patients. The most relevant toxicity of combined RT and sunitinib was hematotoxicity. Eight out of nine patients developed hematotoxicity, four out of nine patients hematotoxicity grade 3 (CTCAE 4.0) and one patient had a dose limiting grade 4 lymphopenia. According to the 3 + 3 design of the trial, the recommended dose of sunitinib for further trials is 37.5 mg given daily and continuously per os starting two weeks prior to the first day and until the last day of RT.

Combined anti-angiogenic treatment was evaluated in several other trials: Pazopanib, sorafenib, sunitinib and bevacizumab were administered concurrently with RT to determine toxicity of combined treatment as a primary endpoint and to explore its efficacy (Table [4](#Tab4){ref-type="table"}) \[[@CR12]--[@CR17]\]. All but one study demonstrated that the combination of RT with anti-angiogenic drugs does not result in excessive toxicity, does not interfere with a full dose administration of RT and is not associated with higher than expected postoperative morbidity. The toxicity profile of combined treatment reflects the toxicity profile of the administered anti-angiogenic drug(e.g. hepatotoxicity in case of pazopanib or hematotoxicity in case of sunitinib) meaning that the combination of the anti-angiogenic drug with radiation therapy did not lead to unexpected adverse events. It is remarkable though, that in the trials the proportions of patients who suffered from grade 3 toxicities were generally higher in the combination with RT compared to anti-angiogenic monotherapy (e.g. hepatotoxicity in case of pazopanib or hematotoxicity in case of sunitinib) \[[@CR18], [@CR19]\]. The increased grade of known and typical toxicities may be attributed to the combination with RT. It is well known that the RT dose administered to the bone marrow has a relevant and overproportional influence on the occurrence and severity of hematotoxicity when combined with chemotherapy as compared to RT alone \[[@CR20], [@CR21]\]. The same appears to be true for concurrent treatment with anti-angiogenic agents. Yet, there is no obvious explanation for increased hepatotoxicity of combined treatment compared to anti-angiogenic drug monotherapy since hepatotoxicity was also increased in patients with extremity tumors with no radiation dose to the liver \[[@CR15]\]. Lewin et al. published the only trial that resulted in unacceptable toxicity with severe hepatotoxicity and hematotoxicity when RT was combined with sunitinib in extremity STS \[[@CR13]\]. Their results contradict our own phase I trial and the results of Sunyach et al. who presented their data on combined RT and sunitinib in irresectable extremity STS during the conference of the connective tissue oncology society 2014 \[[@CR16]\]. In principal, the three trials used similar treatment regimens. Yet, Lewin et al. administered a higher starting dose (50 mg for two weeks followed by 25 mg thereafter) which may have resulted in higher toxicity.Table 4Trials evaluating preoperative anti-angiogenic treatment and RT in STSAuthorEvaluated patientsTreatment regimenTumor sitePatients with toxicity (CTCAE) ≥ grade 3Type of toxicity (CTCAE) ≥ grade 3Path. response: ≥ 90 % non-viable tissueHaas 201511Pazopanib/RTExtremity (*n* = 11)3/11Hepatotoxicity4/10Canter 20148Sorafenib/RTExtremity (*n* = 8)4/8Skin rash (*n* = 2), anemia, perirectal abscess, supraventricular tachycardia3/8Yoon 201120Bevacizumab/RTExtremity (*n* = 13) Retro (*n* = 6) Trunk (*n* = 1)4/20Hepatotoxicity, hypertension7/20Lewin 20149Sunitinib/RTExtremity (*n* = 9)7/9Hepatotoxicity, hematotoxicity, hyponatremia, hyperglycemia, skin rashNot reportedJakob 201516Sunitinib/RTExtremity (*n* = 5) Retro (*n* = 10) Trunk (*n* = 1)8/16Hematotoxicity, hand-foot-syndrome5/16Sunrase (this trial)9Sunitinib/RTExtremity (*n* = 3) Retro (*n* = 4) Trunk (*n* = 2)5/9Hematotoxicity3/9Sunyach 201410Sunitinib/RTExtremity (*n* = 10)Only DLT reportedThrombopenia grade 4 (*n* = 1), no other dose limiting toxicityNot applicable, therapy given for unresectable tumors

The aim of combining anti-angiogenic drugs and RT is to increase RT efficacy and to improve local tumor control. None of the above mentioned trials was designed as a phase II or III trial. Nevertheless, most of the authors presented data on pathological response as a surrogate marker of treatment efficacy (Table [4](#Tab4){ref-type="table"}). Although the evaluation of pathologic response has not been standardized until recently and the fraction of non-viable tumor in the resection specimen depends on histological subtype, it may be used to estimate the efficacy of combined modality treatment in general \[[@CR22]\]. Noteworthy, more than a third of the treated patients had tumors with less than 10 % viable tumor cells in all five trials that reported pathologic response (Table [4](#Tab4){ref-type="table"}). This proportion appears to be significantly higher than what would be expected after preoperative RT alone \[[@CR23]\]. This implies that RT and anti-angiogenic drugs indeed have additive effects. Serum biomarkers of angiogenesis and functional imaging may be alternative surrogate markers for treatment response. Yoon et al. and Lewin et al. performed functional imaging studies after the run-in phase of bevacizumab or sunitinib and after combined treatment, respectively \[[@CR13], [@CR17]\]. Both groups applied different imaging techniques (perfusion CT vs. PET-CT and functional MRI) and found heterogeneous results after anti-angiogenic monotherapy (no influence on median blood flow vs. increased hypoxia, respectively) whereas combined treatment led to decreased blood flow and tumor hypoxia, respectively. Canter et al. evaluated the course of the angiogenesis markers VEGF, EGF and PDGF during neoadjuvant treatment \[[@CR14]\]. Overall, there was no significant difference in serum levels between treatment responders and non-responders. These results demonstrate the difficulty to define reliable predictors of response to combined RT and anti-angiogenic treatment. With PAZNTIS, a phase II/III trial has already been initiated by the American Children's Oncology Group that is sponsored by the NCI. The trial will test preoperative RT vs. pazopanib/RT vs. chemotherapy/RT vs. pazopanib/chemotherapy/RT (ClinicalTrials.gov Identifier: NCT02180867). The PAZNTIS trial will use pathologic response with a cut off at 90 %, serial PET-CT imaging and circulating DNA as surrogate markers of response. Pediatric as well as adult patients may be included with a number of restrictions in the eligibility criteria for recruitment into the different treatment arms. These restrictions and the fact that this is a four arm study with pediatric and adult patients will render results difficult to interpret. Yet, no other phase II/III study of combined treatment has been initiated so far.

Conclusions {#Sec14}
===========

The combination of anti-angiogenic drugs and RT is feasible and toxicity of combined treatment is tolerable. Surgery appears to be safe after concurrent treatment regimens. Further trials need to take into account histological subtypes. Surrogate markers of tumor response are necessary to define the efficacy of neoadjuvant combined RT and anti-angiogenic drug treatment in STS.
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